RecruitingNCT07615426
Aticaprant added to treatment for schizophrenia
About this title
Read the official source — NCT07615426This study evaluates the safety of Aticaprant for people with schizophrenia.
Medication studyAges 18–60United States
Understand this study
What is this study about?
This study evaluates the safety of Aticaprant for people with schizophrenia.
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria apply.
- Listed locations
- Garden Grove and 7 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 2, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 64
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT07615426
- Official title
Show the full official title
A Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Phase 1b Study to Investigate the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
Recruitment & locations
RecruitingGarden Grove · Atlanta · Chicago
5 more locations
- Kalamazoo
- Cedarhurst
- Staten Island
- Austin
- Richardson
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the safety of Aticaprant for people with schizophrenia.
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Does this study involve medication?
Yes. The study involves medication, including Aticaprant and Placebo.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
